ProKidney Corp (NASDAQ:PROK) has a beta value of -93.35% and has seen 818.02 shares traded in the last trading session. The company, currently valued at $193.21M, closed the last trade at $0.70 per share which meant it lost -$3.8 on the day or 0.66% during that session. The PROK stock price is -292.86% off its 52-week high price of $2.75 and 34.29% above the 52-week low of $0.46. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.81 million shares traded. The 3-month trading volume is 2.20 shares.
The consensus among analysts is that ProKidney Corp (PROK) is Buy stock at the moment, with a recommendation rating of 39.87. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 6 have rated it as a Hold, with 5 advising it as a Buy. 0 have rated the stock as Underweight.
ProKidney Corp (NASDAQ:PROK) trade information
Sporting 0.66% in the green in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the PROK stock price touched $0.70 or saw a rise of 31.37%. Year-to-date, ProKidney Corp shares have moved -77.39%, while the 5-day performance has seen it change -26.33%. Over the past 30 days, the shares of ProKidney Corp (NASDAQ:PROK) have changed -16.80%. Short interest in the company has seen 16.52 million shares shorted with days to cover at 26.84.
Wall Street analysts have a consensus price target for the stock at $5, which means that the shares’ value could jump 86.0% from current levels. The projected low price target is $3.0 while the price target rests at a high of $6.0. In that case, then, we find that the current price level is -757.14% off the targeted high while a plunge would see the stock gain -328.57% from current levels.
ProKidney Corp (PROK) estimates and forecasts
The company’s shares have lost -64.13% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 11.32% – over the past 5 years. Earnings growth for 2025 is a modest 9.74% while over the next 5 years, the company’s earnings are expected to decrease by -2.31%.
PROK Dividends
ProKidney Corp is expected to release its next earnings report on 2025-May-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ProKidney Corp (NASDAQ:PROK)’s Major holders
The top two institutional holders are MORGAN STANLEY with over 14.45 million shares worth more than $35.54 million. As of 2024-06-30, MORGAN STANLEY held 19.034% of shares outstanding.
The other major institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, with the holding of over 9.34 million shares as of 2024-06-30. The firm’s total holdings are worth over $22.98 million and represent 12.306% of shares outstanding.
